b. The date the Commission finally issues its Compliant and its Decision and Order.

5. Raytheon waives all rights to contest the validity of this Interim Agreement.

6. For the purpose of determining or securing compliance with this Interim Agreement, subject to any legally recognized privilege and applicable United States Government national security requirements, and upon written request, and on reasonable notice, Raytheon shall permit any duly authorized representative or representatives of the Commission:

a. Access, during the office hours of Raytheon and in the presence of counsel, to inspect and copy all books, ledgers, accounts, correspondence, memoranda, and other records and documents in the possession or under the control of Raytheon relating to compliance with this Interim Agreement; and

b. Upon five (5) days' notice to Raytheon and without restraint or interference from it, to interview officers, directors, or employees of Raytheon, who may have counsel present, regarding any such matters.

7. This Interim Agreement shall not be binding until accepted by the Commission.

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission (''Commission'') has accepted subject to final approval an agreement containing a proposed Consent Order from Raytheon Company (''Raytheon''), which prohibits Raytheon from gaining access to any non-public information in the possession of Electrospace Systems, Inc. (''ESI'') related to the Submarine High Data Rate Satellite Communications Terminal (''Submarine HDR Terminal'') to be procured by the United States Department of the Navy, or disclosing any such information in its possession to ESI. In addition, the Commission has accepted an Interim Agreement which prohibits Raytheon from receiving any non-public information related to the Submarine HDR Terminal from ESI, or giving any such non-public information in its possession to ESI.

The proposed Consent Order has been placed on the public record for sixty (60) days for reception of comments by interested persons. Comments received during this period will become part of the public record. After sixty (60) days, the Commission will again review the agreement and the comments received, and will decide whether it should withdraw from the agreement or make final the agreement's proposed Order.

Pursuant to a Stock Purchase Agreement dated April 4, 1996, Raytheon proposed to purchase all of the voting securities of Chrysler Technologies Holding, Inc. (''CTH'') for approximately $455 million. ESI is a wholly-owned subsidiary of CTH. The proposed Complaint alleges that the acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, in the market for the research, development, manufacture and sale of Submarine HDR Terminals.

The Submarine HDR Terminal is a satellite communications system for use on U.S. Navy submarines that is capable of, among other things, transmitting and receiving both super high frequency and extremely high frequency signals. Initial proposals (bids) for the Navy's procurement of the Submarine HDR Terminal were due on April 15, 1996, and Raytheon submitted an initial proposal. An initial proposal was also submitted by GTE Corporation, for which ESI is a second-tier subcontractor supplying the antenna/terminal controls (an extremely small portion of the overall system). Having received initial proposals, the Navy now intends to hold discussions that may culminate in a ''Best And Final Offer'' competition. At this point in the competition for the Navy's Submarine HDR Terminal, the market is highly concentrated, and effective new entry is unlikely to occur in a timely manner.

In its capacity as supplier of the antenna/terminal controls for the GTE proposal, ESI already possesses a significant amount of competitively sensitive information concerning the GTE proposal, and may be in a position to acquire even more such information during the period from the present until the competition is concluded. The upcoming competition for the Navy's Submarine HDR Terminal could be jeopardized if either Raytheon or ESI gains access to competitively sensitive information in the other's possession as a result of the proposed acquisition. The proposed Consent Order remedies this antitrust concern by prohibiting the exchange of competitively sensitive information between Raytheon and ESI. Other than the exchange of information, the proposed acquisition is unlikely to have an anticompetitive effect due to, among other reasons, the fact that ESI's role on the GTE proposal is extremely small.

Under the provisions of the Consent Order, Raytheon is also required to provide the Commission with a report of compliance with the Order within twenty (20) days of the date the Order becomes final, and annually thereafter until the Navy either: (1) selects only one Submarine HDR Terminal supplier; or (2) cancels the Submarine HDR Terminal procurement entirely.

The purpose of this analysis is to facilitate public comment on the proposed Consent Order, and it is not intended to constitute an official interpretation of the agreement and proposed Order, or to modify in any way their terms.

Donald S. Clark,

Secretary.

[FR Doc. 96–15731 Filed 6–19–96; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30 DAY–13]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request more information on these projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer at (404) 639–7090. Send written comments to Wilma Johnson, CDC Reports Clearance Officer, 1600 Clifton Road, MS–D24, Atlanta, GA 30333. Written comments should be received within 30 days of this notice.

The following requests have been submitted for review since the last publication date on May 29, 1996.

Proposed Project

1. Assessment of the Training Needs of Clinical and Environmental Laboratories—New—The National Laboratory Training Network (NLTN) was established in 1989 through a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Association of State and Territorial Public Health Laboratory Directors (ASTPHLD). Its mission is to enhance the quality of laboratory testing in the nation's laboratories by providing training necessary for laboratory staff to improve their knowledge and skills in all aspects of the testing process. To accomplish

this mission, seven NLTN offices were established at various sites throughout the nation giving all states and territories access to laboratory training through this Network.

NLTN staff was charged with (1) Assessing the training needs (2) developing programs, (3) delivering training and, (4) evaluating the effectiveness of the training. Staff in the seven offices must meet unique needs in the geographical area for which they are responsible. Assessing need is particularly important because more than 100,000 laboratories are doing 16,380 different tests of 631 analytes. NLTN staff must determine the most efficient and effective means to provide training where the greatest need exits.

Need for training in laboratories may be dependent on where the laboratories are located and what population they serve. For example, small laboratories in physicians' offices (POLs) may have very different needs than large, independent laboratories, hospital or state laboratories. Manufacturers develop different products for laboratories that test in high volumes and can afford very sophisticated equipment than for small laboratories that do a limited number of tests. Education and training of personnel in the laboratories also very considerably. Current training needs are vastly different for people who have complete bachelor's degrees in medical technology or a science and those who have no formal laboratory education.

This information collection request is for clearance of a bank of questions from which NLTN staff may periodically select certain ones to use in survey to assess needs—and for flexibility to develop questions in specified formats to address specific practices related to the many tests available. This will allow the NLTN to focus on the appropriate lab type, target audience and test.

Respondents	Number of respondents	Number of responses/respondent	Avg. burden/response (in hrs.)
Laboratory	2,800	1	0.5

The total annual burden is 1400. Send comments to Desk officer, CDC; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503.

Dated: June 14, 1996.

Wilma G. Johnson,

Acting Associate Director of Policy Planning And Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–15718 Filed 6–19–96; 8:45 am]

BILLING CODE 4163–18–P

Agency for Health Care Policy and Research

Notice of Health Care Policy and Research; Special Emphasis Panel Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of July 1996:

Name: Health Care Policy and Research Special Emphasis Panel.

Date and Time: July 10, 1996, 9:30 a.m.

Place: DoubleTree Hotel, 1750 Rockville Pike, Conference Room TBA, Rockville, Maryland 20852.

Open July 10, 9:30 a.m. to 9:45 a.m.
Closed for remainder of meeting.

Purpose: This Panel is charged with conducting the initial review of grant applications proposing medical effectiveness research. The three main areas of emphasis are: (1) Determining what clinical interventions are most effective, cost effective, and appropriate; (2) methods and data to advance effectiveness research; and (3) dissemination and evaluation of the impact of research findings on clinical practice and outcomes.

Agenda: The open session of the meeting on July 10, from 9:30 a.m. to 9:45 a.m., will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C. Appendix 2 and 5 U.S.C. 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Linda Blankenbaker, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1437 x1603.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: June 12, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–15717 Filed 6–19–96; 8:45 am]

BILLING CODE 4160–90–M

Notice of Health Care Policy and Research; Special Emphasis Panel Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of July 1996:

Name: Health Care Policy and Research Special Emphasis Panel.

Date and Time: July 9, 1996, 9:30 a.m.

Place: Agency for Health Care Policy and Research, 2101 E. Jefferson Street, Suite 400, Rockville, Maryland 20852.

Open July 9, 9:30 a.m. to 9:45 a.m.
Closed for remainder of meeting.

Purpose: This Panel is charged with conducting the initial review of grant applications proposing medical effectiveness research. The three main areas of emphasis are: (1) Determining what clinical interventions are most effective, cost effective, and appropriate; (2) methods and data to advance effectiveness research; and (3) dissemination and evaluation of the impact of research findings on clinical practice and outcomes.

Agenda: The open session of the meeting on July 9, from 9:30 a.m. to 9:45 a.m., will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Linda Blankenbaker, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1437 x1603.

Agenda items for this meeting are subject to change as priorities dictate.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–15723 Filed 6–19–96; 8:45 am]

BILLING CODE 4160–90–M

Centers for Disease Control and Prevention

[Announcement 601]

Prevention of HIV Infection in Youth at Risk: Developing Community-Level Strategies That Work

Introduction

The Centers for Disease Control and Prevention (CDC) announces the